Prognostic Role of Carbohydrate Antigen 19 to 9 in Predicting Survival of Patients With Pancreatic Cancer: A Meta-Analysis

Abstract

This study evaluates the prognostic role of carbohydrate antigen 19 to 9 (CA19-9) in predicting survival of pancreatic cancer patients. Literature search was conducted in electronic databases (Google Scholar, Ovid, PubMed, and Science Direct) and study selection was based on precise eligibility criteria. Random-effects meta-analyses were performed to achieve overall estimates of median survival and hazard ratios (HRs) of survival with cutoff defined lower and higher CA19-9 levels before and after surgery or chemotherapy (CT)/radiotherapy (RT) and the changes in CA19-9 levels after any treatment. A total of 41 studies (6519 patients; 42% females; age 63.3 years [95% confidence interval [CI]: 62.2, 64.4]) were included. A pooled HR of 1.79 with a narrow 95% CI (1.58, 2.01) showed that higher CA19-9 levels or less decrease in CA19-9 levels after treatment predicted shorter survival. Median survival in patients with lower and higher preoperative CA19-9 levels was 23.2 months [95% CI: 17.2, 29.2] and 14.0 months [95% CI: 10.9, 17.2], respectively, whereas median survival with lower and higher postoperative CA19-9 levels was 25.0 months [95% CI: 21.9, 28.0] and 13.0 months [95% CI: 10.9, 15.0] respectively. Median survival with lower and higher pre-CT/RT CA19-9 levels was 11.9 months [95% CI: 10.2, 13.6] and 7.7 months [95% CI: 6.2, 9.2], respectively, whereas median survival with lower and higher post-CT/RT CA19-9 levels was 15.1 months [95% CI: 13.2, 17.0] and 10.7 months [95% CI: 7.3, 14.0] respectively. A decrease in CA19-9 levels after treatment was also associated with longer survival. Thus, both pretreatment and posttreatment CA19-9 levels or their changes after treatment have good prognostic value in determining the survival of pancreatic cancer patients.

Keywords

CA19-9 pancreatic cancer prognosis survival predictor

Introduction

Pancreatic cancer is the seventh leading cause of death.¹ Pancreatic exocrine adenocarcinoma accounts for approximately 85% of cases whereas the incidence of pancreatic endocrine tumors is relatively low.² In the United States of America, pancreatic cancer comprises 3% of all cancers and 7% of all cancer-related mortality but in China, it accounts for 19.5% of all cancers.^3,4 It is slightly more common in men than in women.³ Worldwide, the estimated number of new cases of pancreatic cancer in 2018 was 458 918.⁵ Later age, male gender, tobacco use, overweight or obesity, chronic pancreatitis, non-O blood group, diabetes mellitus, a diet high in fat and meat but low in vegetables and folate, occupational exposure to toxicants, family history, and genetic disorders (familial pancreatitis, Lynche syndrome, Peutz-Jeghers syndrome, etc) are important risk factors for pancreatic cancer.^3,6

Pancreatic cancer is a slowly and silently progressing cancer that is usually diagnosed at a late stage.⁷ Inherent resistance to chemotherapy and radiotherapy and its propensity for earlier metastasis makes pancreatic cancer difficult-to-treat cancer.⁸ Five-years survival rate of patients with localized pancreatic cancer is 37%, but for patients with regional and distant metastasis, it is 12% and 3%, respectively.³ At earlier stages, pancreatic cancer remains clinically silent. It is usually detected when the tumor invades surrounding areas or metastases to distant organs. Presenting symptoms which include abdominal or mid-back pain, obstructive jaundice, weight loss, asthenia, anorexia, nausea, duodenal obstruction, and gastrointestinal hemorrhage are usually dependent on the anatomical location of the tumor.^6,9 Diagnosis is mainly based on computed tomographic examinations which can also help in cancer staging and the prediction of surgical resection.¹⁰ Serum levels of carbohydrate antigens 19 to 9 (CA19-9), CA125, CA242, carcinoembryonic antigen (CEA), and tumor-specific growth factors are important markers in the diagnosis of pancreatic cancer.¹¹

Although pancreatic cancer is usually associated with a poor prognosis, several factors affect the prognosis. These include treatment, tumor location, stage, metastases, leucocyte count, hemoglobin, albumin, blood urea nitrogen, lactic dehydrogenase, alkaline phosphatase, aspartate aminotransferase, glutamic-pyruvic transaminase, CEA, CA19-9, CA125, and CA242.^11-¹³ The CA19-9, also called sialylated Lewis blood group antigen, is an important diagnostic and prognostic serum biomarker. Higher pretreatment CA19-9 levels are usually associated with a poor prognosis. Moreover, postoperative CA19-9 levels or the changes in CA19-9 levels after treatment can also provide prognostic information.^14,15 Several studies have reported survival outcomes of pancreatic cancer patients in association with CA19-9 levels but there is no systematic review of this area. We hypothesized that higher CA19-9 levels in pancreatic cancer patients predict shorter survival. The present study aimed to evaluate the prognostic role of CA19-9 in predicting the survival of pancreatic cancer patients by conducting a systematic review and performing a meta-analysis of survival outcomes in association with pretreatment and posttreatment CA19-9 levels or posttreatment changes in CA19-9 levels.

Materials and Methods

This meta-analysis was performed by following Meta-Analysis of Observational Studies in Epidemiology guidelines.

Inclusion and Exclusion Criteria

Inclusion criteria were: A study (a) investigated the association between CA19-9 levels and survival of pancreatic cancer patients; (b) reported the hazard ratio (HR) depicting the associations between CA19-9 and survival; (c) reported the survival of patients with high and low CA19-9 levels before or after treatment (surgery and/or chemotherapy/radiotherapy); and (d) reported survival outcomes with the changes in CA19-9 levels after treatment. Exclusion criteria were: a study (a) reported the outcomes in cancer patients without distinction of pancreatic cancer; (b) reported the association of CA19-9 with other prognostic factors but not survival; (c) reported the survival outcomes with the combined use of markers; and (d) qualitative studies.

Literature Search

The literature search was conducted in Google Scholar, Ovid, PubMed, and Science Direct databases. Key terms used for literature search included pancreas, pancreatic, cancer, carcinoma, adenocarcinoma, prognosis, prognostic, predictor, carbohydrate antigen, CA19-9, sialylated Lewis blood group antigen, follow-up, survival, recurrence, and hazard. The literature search strategy is presented in Appendix S1. References lists of important research and review articles were also screened. Literature search encompassed original research articles published in English before September 2020.

Data Analyses

Demographic data, cancer stage, treatment, tumor size and location, performance status, pretreatment/posttreatment CA19-9 levels, CA19-9 cutoffs, survival outcome data, and HRs showing prognostic information were extracted from research articles of the included studies. Quality assessment of the included studies was performed with the Newcastle-Ottawa Scale for the Quality Assessment of Cohort Studies. Two reviewers extracted data and performed quality assessment independently and then outputs of both reviewers were unified. Interrater reliability was high. However, when these reviewers found difficulty in deciding, they sought the help of one or more co-researchers.

The HRs of survival between higher and lower CA19-9 levels or the changes in CA19-9 levels after treatment were pooled under the random-effects model to achieve overall and subgroup estimates. Median survival of patients with cutoff-defined lower and higher CA19-9 levels or the changes in CA19-9 levels after treatment were also pooled under the random-effects model by deriving variance from sample sizes. In these meta-analyses, the DerSimon-Liard method was used to achieve pooled estimates.

Subgroup analyses were performed for preoperative, pretherapy (chemotherapy; CT) and/or radiotherapy; RT), postoperative, post-CT/RT CA19-9 levels, or the changes in CA19-9 levels after any treatment. A sensitivity analysis was performed by excluding all studies with CA19-9 cutoff values other than the normal reference (37 U/mL). The I² index was used to estimate the proportion of observed variance reflecting true variance rather than sampling error. High I² values inform that true effect varies from study to study. All statistical analyses were performed with Stata software (version 12; Stata Corporation, College Station).

Results

Forty-one studies^{13-
52} were included in this meta-analysis (Figure 1). In these studies, 6519 patients with pancreatic cancer of which 42% (95% confidence interval [CI]: 40, 45) were females were evaluated. The average age of the patients was 63.3 years [95% CI: 62.2, 64.4]. Cancer was in the head of pancreas in 65% [95% CI: 57, 73] and in the body or tail in 31% [95% CI: 25, 39] of patients. Average pretreatment CA19-9 levels in these patients were 519 U/mL [95% CI: 362, 677]. Important characteristics of the included studies are presented in Table S1 (Supporting Information File). The quality of the included studies was good according to the Newcastle-Ottawa Scale (Table S2).

Figure 1.

A flowchart of study screening and selection process.

A pooled analysis of the HRs of survival between higher and lower CA19-9 levels yielded an overall HR of 1.79 [95% CI: 1.58, 2.01] which showed that higher CA19-9 levels were associated with shorter survival (Figure 2). Similar pooled HRs were observed for preoperative (1.70 [95% CI: 1.39, 2.00]), postoperative (2.07 [95% CI: 1.64, 2.49]), pretherapy (1.53 [95% CI: 1.20, 1.85]), and for the changes in CA19-9 levels after treatment (2.07 [1.31, 2.84]) subgroups. In these analyses, confidence intervals of pooled estimates were stringent and I² values ranged between 5% and 53%.

Figure 2.

A forest graph showing the outcomes of meta-analysis of hazard ratios of survival between higher and lower preoperative, postoperative, pretreatment, posttreatment carbohydrate antigen 19 to 9 (CA19-9) levels, and the changes in CA19-9 levels after treatment.

In the meta-analysis of studies that reported the survival with cutoff-defined lower and higher CA19-9 levels, median overall survival was 23.2 months [95% CI: 17.2, 29.2] with lower and 14.0 months [95% CI: 10.9, 17.2] with higher than cutoff preoperative CA19-9 levels. Median survival was 25.0 months [95% CI: 21.9, 28.0] with lower and 13.0 months [95% CI: 10.9, 15.0] with higher than cutoff postoperative CA19-9 levels. Median survival with lower and higher pre-CT/RT CA19-9 levels was 11.9 months [95% CI: 10.2 13.6] and 7.7 months [95% CI: 6.2, 9.2], respectively, whereas the median survival with lower and higher post-CT/RT CA19-9 levels was 15.1 months [95% CI: 13.2, 17.0] and 10.7 months [95% CI: 7.3, 14.0], respectively (Figure S1). In a sensitivity analysis with studies that used 37 U/mL cutoff for CA19-9 level to differentiate between lower and higher CA19-9 levels, the outcomes were not much different from those of the main meta-analysis (Figure S2).

In the meta-analysis of the changes in CA19-9 levels after treatment, it was found that the survival was longer with a cutoff defined decrease in CA19-9 levels after treatment. Survival was 11.1 months [95% CI: 10.0, 12.3] with >15% to 25% decrease, and 7.4 months [95% CI: 5.6, 9.2] with <15% to 25% decrease in CA19-9 levels after CT/RT. Similarly, survival was 11.1 months [95% CI: 9.6, 12.7] and 7.9 months [95% CI: 6.5, 9.4] with >50% and <50% decrease in CA19-9 levels after CT/RT, respectively (Figure 3).

Figure 3.

A forest graph showing the outcomes of meta-analysis of survival rates with higher and lower changes in CA19-9 levels after treatment with different cutoff values.

Discussion

This meta-analysis has estimated a HR of 1.8 with narrow credibility limits to show that higher CA19-9 levels predict shorter survival in pancreatic cancer patients. Survival was considerably longer with cutoff-defined lower CA19-9 levels for both pretreatment and posttreatment samples. A cutoff-defined decrease in CA19-9 levels after treatment was also associated with longer survival. Different cutoff values for distinguishing lower and higher CA19-9 levels or their changes after treatment had generally similar survival outcomes.

Despite surgical resection even with no residual tumor, not all patients achieve a decrease in postoperative CA19-9 levels. It has been suggested that sustained elevations in CA19-9 levels may be due to micro-metastases such as hepatic micro-metastases which remain undetected at the time of surgery.⁴⁰ Patients with persistently higher CA19-9 levels are more likely to have metastases and perineural invasion.⁸ The CA19-9 levels can be found elevated in benign conditions like pancreatitis which is frequently found in pancreatic cancer patients. Another source of CA19-9 is cholestasis in which it is excreted from the biliary epithelium.²⁸ Such conditions can also contribute to persistently higher CA19-9 levels.

Several differing cutoff values ranging from 35 to 1212 U/mL were used by the included studies to differentiate between lower and higher CA19-9 levels. In a sensitivity analysis of studies that used normal reference value (37 U/mL) as the cutoff to differentiate between higher and lower CA19-9 levels, we could not find much difference in survival outcomes from those of the main meta-analysis. Individual studies that used multiple cutoffs also found similar outcomes. Kondo et al reported similar low versus high survival differences with the cutoffs of 37, 100, 200, and 500 U/mL. Koom et al¹⁴ and Yoo et al⁵⁰ also found similar survival outcomes with different cutoffs. Kondo et al¹⁵ and Koom et al¹⁴ found postoperative CA19-9 levels to predict differential survival better than preoperative levels. However, Yoo et al⁵⁰ who also used several cutoffs, found both preoperative and postoperative CA19-9 levels to be equally useful to differentiate survival with lower and higher CA19-9 levels.

We have also observed a variation in the use of cutoff values by the individual studies in studying the survival outcomes with the changes in CA19-9 levels after treatment. These cutoffs ranged from 20% to 94% change in CA19-9 levels after treatment. However, differences in survival outcomes were generally similar with different cutoffs. It is suggested that a decrease from preoperative levels to postoperative levels or postoperative levels alone can help in the stratification of patients for further treatments.²⁰ We have noticed that, in general, survival shortened with increasing cutoff values for both pretreatment and posttreatment CA19-9 levels in studies that used multiple cutoffs.^{14,15,19,20,50} However, this trend was not clear for the decrease in CA19-9 levels after treatment. Ko et al found an increase in survival of 9.6, 10.8, and 12 months with 25%, 50%, and 75% decrease in posttherapy CA19-9 levels, respectively, but Koom et al¹⁴ and Yoo et al⁵⁰ did not find such a dose–response change in the survival with multiple cutoffs of percent decrease in CA19-9 levels after treatment.³⁴

It is usually accepted that patients with higher preoperative CA19-9 levels have a higher tumor burden and a higher risk of earlier death.²⁰ In patients with potentials for tumor resection, the preoperative CA19-9 levels predict tumor aggressiveness and disease burden which can help in disease staging as well as in decision-making for adjuvant treatment. Moreover, postoperative CA19-9 levels may also help in predicting the outcomes of adjuvant therapy.^23,28 A recently published meta-analysis has reported that a decrease or normalization of CA19-9 levels after neoadjuvant treatment was associated with better survival in pancreatic cancer patients.⁵³ A decrease in CA19-9 levels after treatment is also predictive of better prognosis in terms of patient's response to treatment, and remission of disease and consequently improved survival.⁵⁴

Among the limitations of the present study, high I² values observed in the meta-analyses of survival with lower and higher CA19-9 levels are an important consideration. This high level of between-studies inconsistency in outcomes could be due to the use of several and wide-ranging cutoffs, clinical characteristics, and tumor stage. However, in the meta-analysis of HRs, the I² values were low to moderate which endorsed the outcomes of meta-analyses of survival with low and high CA19-9 levels.

In conclusion, this meta-analysis found that cutoff-defined lower pretreatment or posttreatment CA19-9 levels in pancreatic cancer patients predict longer survival. Moreover, cutoff-defined decreases in CA19-9 levels after treatment were also associated with better survival. Different cutoff values to differentiate between lower and higher CA19-9 levels or the changes in CA19-9 levels after treatment had generally similar survival outcomes.

Supplemental Material

sj-docx-1-tct-10.1177_15330338211043030 - Supplemental material for Prognostic Role of Carbohydrate Antigen 19 to 9 in Predicting Survival of Patients With Pancreatic Cancer: A Meta-Analysis

Supplemental material, sj-docx-1-tct-10.1177_15330338211043030 for Prognostic Role of Carbohydrate Antigen 19 to 9 in Predicting Survival of Patients With Pancreatic Cancer: A Meta-Analysis by Yong-Ming Kang, Hao Wang, Ran Li and Gu Pan in Technology in Cancer Research & Treatment

Supplemental Material

sj-jpg-2-tct-10.1177_15330338211043030 - Supplemental material for Prognostic Role of Carbohydrate Antigen 19 to 9 in Predicting Survival of Patients With Pancreatic Cancer: A Meta-Analysis

Supplemental material, sj-jpg-2-tct-10.1177_15330338211043030 for Prognostic Role of Carbohydrate Antigen 19 to 9 in Predicting Survival of Patients With Pancreatic Cancer: A Meta-Analysis by Yong-Ming Kang, Hao Wang, Ran Li and Gu Pan in Technology in Cancer Research & Treatment

Supplemental Material

sj-jpg-3-tct-10.1177_15330338211043030 - Supplemental material for Prognostic Role of Carbohydrate Antigen 19 to 9 in Predicting Survival of Patients With Pancreatic Cancer: A Meta-Analysis

Supplemental material, sj-jpg-3-tct-10.1177_15330338211043030 for Prognostic Role of Carbohydrate Antigen 19 to 9 in Predicting Survival of Patients With Pancreatic Cancer: A Meta-Analysis by Yong-Ming Kang, Hao Wang, Ran Li and Gu Pan in Technology in Cancer Research & Treatment

Footnotes

Abbreviations

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by Research Project of Health Commission of Heilongjinag Province (2019-133).

ORCID iD

Gu Pan

Supplemental Material

Supplemental material for this article is available online.

References

Bray

Ferlay

Soerjomataram

Siegel

Torre

Jemal

. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi:10.3322/caac.21492

Ilic

. Epidemiology of pancreatic cancer. World J Gastroenterol. 2016;22(44):9694-9705. doi:10.3748/wjg.v22.i44.9694

American Cancer Society. Pancreatic Cancer. Available at https://www.cancer.org/cancer/pancreatic-cancer.html.

International Agency for Research on Cancer. Global cancer observatory. Cancer Today. https://gco.iarc.fr/today/online-analysis-table.

Lin

Yang

Jin

. Current status and progress of pancreatic cancer in China. World J Gastroenterol. 2015;21(26):7988-8003. doi:10.3748/wjg.v21.i26.7988

Vincent

Herman

Schulick

Hruban

Goggins

. Pancreatic cancer. Lancet. 2011;378(9791):607-620. doi:10.1016/s0140-6736(10)62307-0

Ansari

Tingstedt

Andersson

, et al. Pancreatic cancer: yesterday, today and tomorrow. Future Oncol. 2016;12(16):1929-1946. doi:10.2217/fon-2016-0010

Abdel-Misih

Hatzaras

Schmidt

, et al. Failure of normalization of CA19-9 following resection for pancreatic cancer is tantamount to metastatic disease. Ann Surg Oncol. 2011;18(4):1116-1121. doi:10.1245/s10434-010-1397-1

Hidalgo

. Pancreatic cancer. N Engl J Med. 2010;362(17):1605-1617. doi:10.1056/NEJMra0901557

10.

Karmazanovsky

Fedorov

Kubyshkin

Kotchatkov

. Pancreatic head cancer: accuracy of CT in determination of resectability. Abdom Imaging. 2005;30(4):488-500. doi:10.1007/s00261-004-0279-z

11.

Chen

Gao

Chen

, et al. Serum CA242, CA199, CA125, CEA, and TSGF are biomarkers for the efficacy and prognosis of cryoablation in pancreatic cancer patients. Cell Biochem Biophys. 2015;71(3):1287-1291. doi:10.1007/s12013-014-0345-2

12.

Stocken

Hassan

Altman

, et al. Modelling prognostic factors in advanced pancreatic cancer. Br J Cancer. 2008;99(6):883-893. doi:10.1038/sj.bjc.6604568

13.

Zhang

Dai

Yuan

Tao

. Prognostic factors in patients with pancreatic cancer. Exp Ther Med. 2012;3(3):423-432. doi:10.3892/etm.2011.412

14.

Koom

Seong

Kim

Pyun

Song

. CA 19-9 As a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009;73(4):1148-1154. doi:10.1016/j.ijrobp.2008.06.1483

15.

Kondo

Murakami

Uemura

, et al. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol. 2010;17(9):2321-2329. doi:10.1245/s10434-010-1033-0

16.

Asaoka

Miyamoto

Maeda

, et al. Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer. Pancreatology. 2016;16(3):434-440. doi:10.1016/j.pan.2015.10.006

17.

Berger

Meszoely

Ross

Watson

Hoffman

. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2004;11(7):644-649. doi:10.1245/aso.2004.11.025

18.

Berger

Garcia

Jr. Hoffman

, et al. Postresection CA 19–9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol. 2008;26(36):5918-5922. doi:10.1200/jco.2008.18.6288

19.

Dong

Yang

Zhang

, et al. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study. World J Surg Oncol. 2014;12(171): 2897-2909. doi:10.1186/1477-7819-12-171

20.

Ferrone

Finkelstein

Thayer

Muzikansky

Fernandez-delCastillo

Warshaw

. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol. 2006;24(18):2897-2902. doi:10.1200/jco.2005.05.3934

21.

Gogas

Lofts

Evans

Daryanani

Mansi

. Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas? Br J Cancer. 1998;77(2):325-328. doi: 10.1038/bjc.1998.50

22.

Lan

Pei

Yang

Liu

Xiao

. Applicative value of serum CA19-9, CEA, CA125 and CA242 in diagnosis and prognosis for patients with pancreatic cancer treated by concurrent chemoradiotherapy. Asian Pac J Cancer Prev. 2015;16(15):6569-6573. doi:10.7314/apjcp.2015.16.15.6569

23.

Hallemeier

Botros

Corsini

Haddock

Gunderson

Miller

. Preoperative CA 19-9 level is an important prognostic factor in patients with pancreatic adenocarcinoma treated with surgical resection and adjuvant concurrent chemoradiotherapy. Am J Clin Oncol. 2011;34(6):567-572. doi:10.1097/COC.0b013e3181f946fc

24.

Halm

Schumann

Schiefke

Witzigmann

Mössner

Keim

. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer. 2000;82(5):1013-1016. doi:10.1054/bjoc.1999.1035

25.

Haas

Heinemann

Kullmann

, et al. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol. 2013;139(4):681-689. doi:10.1007/s00432-012-1371-3

26.

Hata

Sakamoto

Yamamoto

, et al. Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol. 2012;19(2):636-641. doi:10.1245/s10434-011-2020-9

27.

Hess

Glimelius

Grawe

, et al. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol. 2008;9(2):132-138. doi:10.1016/s1470-2045(08)70001-9

28.

Humphris

Chang

Johns

, et al. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol. 2012;23(7):1713-1722. doi:10.1093/annonc/mdr561

29.

Ikeda

Okada

Tokuuye

Ueno

Okusaka

. Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy. Cancer. 2001;91(3):490-495. doi:10.1002/1097-0142(20010201)91:3 < 490::aid-cncr1027>3.0.co;2-l

30.

Imaoka

Shimizu

Senda

, et al. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: a retrospective cohort study. Pancreatology. 2016;16(4):658-664. doi:10.1016/j.pan.2016.04.007

31.

Katz

Hanlon

Lanciano

Hoffman

Coia

. Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy. Int J Radiat Oncol Biol Phys. 1998;41(2):393-396. doi:10.1016/s0360-3016(98)00058-3

32.

Kim

Koh

Chie

, et al. Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy. Int J Clin Oncol. 2017;22(6):1069-1075. doi:10.1007/s10147-017-1129-7

33.

Kinsella

Seo

Willis

, et al. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer. Am J Clin Oncol. 2008;31(5):446-453. doi:10.1097/COC.0b013e318168f6c4

34.

Hwang

Venook

Abbruzzese

Bergsland

Tempero

. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer. 2005;93(2):195-199. doi:10.1038/sj.bjc.6602687

35.

Lee

Chung

, et al. Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma. Yonsei Med J. 2013;54(3):643-649. doi:10.3349/ymj.2013.54.3.643

36.

Liu

Hong

Zhao

Gao

. Effect of perioperative CEA and CA24-2 on prognosis of early resectable pancreatic ductal adenocarcinoma. J Cancer. 2020;11(1):9-15. doi:10.7150/jca.33767

37.

Lundin

Roberts

Kuusela

Haglund

. The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. Br J Cancer. 1994;69(3):515-519. doi:10.1038/bjc.1994.93

38.

Maisey

Norman

Hill

Massey

Oates

Cunningham

. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer. 2005;93(7):740-743. doi:10.1038/sj.bjc.6602760

39.

Micke

Bruns

Kurowski

, et al. Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy. Int J Radiat Oncol Biol Phys. 2003;57(1):90-97. doi:10.1016/s0360-3016(03)00524-8

40.

Motoi

Murakami

Okada

, et al. Sustained elevation of postoperative serum level of carbohydrate antigen 19-9 is high-risk stigmata for primary hepatic recurrence in patients with curatively resected pancreatic adenocarcinoma. World J Surg. 2019;43(2):634-641. doi:10.1007/s00268-018-4814-4

41.

Bai

Mao

, et al. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol. 2005;31(2):164-169. doi:10.1016/j.ejso.2004.09.007

42.

Reitz

Gerger

Seidel

, et al. Combination of tumour markers CEA and CA19-9 improves the prognostic prediction in patients with pancreatic cancer. J Clin Pathol. 2015;68(6):427-433. doi:10.1136/jclinpath-2014-202451

43.

Saad

Machado

Wajsbrot

, et al. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int J Gastrointest Cancer. 2002;32(1):35-41. doi:10.1385/ijgc:32:1:35

44.

Song

Chen

Guo

Lian

. Combined pretreatment serum CA19-9 and neutrophil-to-lymphocyte ratio as a potential prognostic factor in metastatic pancreatic cancer patients. Medicine (Baltimore). 2018;97(4):e9707. doi:10.1097/md.0000000000009707

45.

Sperti

Pasquali

Catalini

, et al. CA 19-9 As a prognostic index after resection for pancreatic cancer. J Surg Oncol. 1993;52(3):137-141. doi:10.1002/jso.2930520302

46.

Stemmler

Stieber

Szymala

, et al.

Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin?

Onkologie. 2003;26(5):462-467. doi:10.1159/000072980

47.

Wong

Hwang

Venook

Bergsland

Tempero

. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas. 2008;37(3):269-274. doi:10.1097/MPA.0b013e31816d8185

48.

Huang

Wang

, et al. Relationship between serum CA19-9 and CEA levels and prognosis of pancreatic cancer. Ann Transl Med. 2015;3(21):328. doi:10.3978/j.issn.2305-5839.2015.11.17

49.

Liu

Xiang

, et al. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma. Surgery. 2017;161(2):373-384. doi:10.1016/j.surg.2016.08.005

50.

Yoo

Lee

Woo

, et al. Pretreatment carbohydrate antigen 19-9 level indicates tumor response, early distant metastasis, overall survival, and therapeutic selection in localized and unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2011;81(4):e623-e630. doi:10.1016/j.ijrobp.2011.02.063

51.

Zhao

Liao

Niu

Zhao

. Prognostic significance of SUVmax and serum carbohydrate antigen 19-9 in pancreatic cancer. World J Gastroenterol. 2014;20(19):5875-5880. doi:10.3748/wjg.v20.i19.5875

52.

Zhou

Liu

Wang

, et al. Combination of preoperative CEA and CA19-9 improves prediction outcomes in patients with resectable pancreatic adenocarcinoma: results from a large follow-up cohort. Onco Targets Ther. 2017;10:1199-1206. doi:10.2147/ott.s116136

53.

Sadula

Ren

, et al. The prognostic value of CA19-9 response after neoadjuvant therapy in patients with pancreatic cancer: a systematic review and pooled analysis. Cancer Chemother Pharmacol. 2020;86(6):731-740. doi: 10.1007/s00280-020-04165-2

54.

Poruk

Gay

Brown

, et al. The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med. 2013;13(3):340-351. doi:10.2174/1566524011313030003

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.08 MB

0.80 MB

0.63 MB